<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - IPRATROPIUM BROMIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>IPRATROPIUM BROMIDE</h1>

        <p><a href="../drugClass/PHP34556.html">ANTIMUSCARINICS (INHALED)</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Reversible airways obstruction</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of aerosol</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;5 years</strong><br/>
                20 micrograms 3 times a day.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                20&#8211;40 micrograms 3 times a day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                20&#8211;40 micrograms 3&#8211;4 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Reversible airways obstruction, particularly in chronic obstructive pulmonary disease</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20&#8211;40 micrograms 3&#8211;4 times a day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                250&#8211;500 micrograms 3&#8211;4 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute bronchospasm</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms as required.</li>
              <li class="dose child"><strong>For children 1 month&#8211;4 years</strong><br/>
                125&#8211;250 micrograms as required; maximum 1 mg per day.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                250 micrograms as required; maximum 1 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                500 micrograms as required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe or life-threatening acute asthma</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms every 4&#8211;6 hours as required.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                250 micrograms every 20&#8211;30 minutes for the first 2 hours, then 250 micrograms every 4&#8211;6 hours as required.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                500 micrograms every 4&#8211;6 hours as required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Rhinorrhoea associated with allergic and non-allergic rhinitis</span>,
            </h4>
            <p class="specificity"><span class="route">By intranasal administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 sprays 2&#8211;3 times a day, dose to be sprayed into each nostril.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                2 sprays 2&#8211;3 times a day, dose to be sprayed into each nostril.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>1 metered spray of nasal spray = 21&#8239;micrograms.</p>
            </section>
        
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>The maximal effect of inhaled ipratropium occurs 30&#8211;60 minutes after use; its duration of action is 3 to 6 hours and bronchodilation can usually be maintained with treatment 3 times a day.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Inhaled drugs for asthma can be taken as normal during pregnancy.</p>
            </section>
      </section>




      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> dizziness, nausea in children, epistaxis, nasal dryness, nasal irritation,
              </p>
              <p>
                <strong>uncommon:</strong> laryngospasm, pharyngeal oedema in children, pruritus, stomatitis, vomiting, headache, nausea, pharyngitis in children,
              </p>
              <p>
                <strong>rare:</strong> atrial fibrilation in children, ocular accomodation disorder in children,
              </p>
              <p>
                <strong>veryRare:</strong> gastro-intestinal motility disturbances, palpitations, urinary retention,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph> in adults</h3>
              <p>If dilution of ipratropium bromide nebuliser solution is necessary use only sterile sodium chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Advise patient not to exceed prescribed dose and to follow manufacturer&#8217;s directions.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by inhalation:</strong>
            cystic fibrosis
          </li>
          <li>
              <strong>With intranasal use:</strong>
            avoid spraying near eyes
          </li>
          <li>
              <strong>With intranasal use:</strong>
            bladder outflow obstruction
          </li>
          <li>
              <strong>With intranasal use:</strong>
            cystic fibrosis
          </li>
          <li>
              <strong>With intranasal use:</strong>
            prostatic hyperplasia in adults
          </li>
          <li>
              <strong>With intranasal use:</strong>
            risk of glaucoma in children
          </li>
          <li>
              <strong>With intranasal use:</strong>
            susceptability to angle-closure glaucoma in adults
          </li>
        </ul>
        <ul>
          <li>
              <strong>When used by <ph outputclass="route">inhalation</ph>:</strong>
            <p>
        <i>Acute angle-closure glaucoma</i> has been reported with nebulised ipratropium, particularly when given with nebulised salbutamol (and possibly other beta<sub>2</sub> agonists); care needed to protect the patient's eyes from nebulised drug or from drug powder.</p>
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of IPRATROPIUM BROMIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76336"><a href="../medicinalForm/PHP76336.html" data-target="#PHP76336" data-action="load">Pressurised inhalation</a></div>
            <div id="PHP76316"><a href="../medicinalForm/PHP76316.html" data-target="#PHP76316" data-action="load">Nebuliser liquid</a></div>
            <div id="PHP76322"><a href="../medicinalForm/PHP76322.html" data-target="#PHP76322" data-action="load">Spray</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
